samedan logo
 
 
spacer
home > pmps > spring 2003 > generic medicine - what's in it for the health service?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Generic Medicine - What's in it for the Health Service?

While pharma faces its toughest challenge yet from generics competition, Bluepharma's newly opened Research & Development Services Laboratories will boost the flow of new products through its pharma clients' commercial pipeline while the company continues to expand its contract manufacturing services business.

In March 2003 Bluepharma, a contract production services organisation based in Coimbra, Portugal, a spin-off from Bayer, launched its brand new laboratories offering product research and development services.

This event took place in the same week that Portugal's Government introduced a system of reimbursement by referential pricing (see Generic Medicine - What's in it for the Health Service, page 76), which will pose one of the toughest challenges ever for the nation's pharma industry entering the market for generic medicines.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Patricia Lobo, Editor of PMPS

Dr Luis Filipe Pereira, Minister for Health at Inauguration of Bluepharma's New R&D Laboratories

Dr Paulo Barradas, CEO of Bluepharma

Dr Isolina Mesquita, Director of Operations & Plant Manager

Professor Sergio Simoes, Head of Bluepharma's R&D Laboratory


spacer
Dr Patricia Lobo
spacer
spacer
spacer
Dr Luis Filipe Pereira
spacer
spacer
spacer
Dr Paulo Barradas
spacer
spacer
spacer
Dr Isolina Mesquita
spacer
spacer
spacer
Professor Sergio Simoes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Brooks Introduces Azenta Life Sciences To Advance Innovative Sample Solutions

CHELMSFORD, Mass., Sept. 28, 2021 -- Today Brooks Automation, Inc. (Nasdaq: BRKS) announces Brooks Life Sciences Services and Products businesses will be rebranded under the creation of a new identity Azenta Life Sciences ("Azenta").
More info >>

White Papers

Life Cycle of an Analytical Method - a Case Study on the Monocyte Activation Test

Wickham Laboratories Limited

Pyrogens, a heterogeneous group of fever inducing contaminants, are comprised of microbial and non-microbial compounds; e.g. endotoxin (lipopolysaccharide, LPS) produced by Gram-negative bacteria, lipoteichoic acid (LTA) from Gram-positive bacteria, bacterial DNA (CpG-motive), endogenous pyrogens, virus and fungi particles or even fragments of packaging materials, plastic and dust. Contaminat ion wi th pyrogens in pharmaceutical products, biotherapeutics and on medical devices can lead to life threatening fever reactions. To ensure consumer safety, pyrogen testing is mandatory for parenteral products and medical devices.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement